Fujifilm's CDMO arm plots massive $2B plant in the US for broad range of therapeutics
Buoyed by interest from major Covid-19 vaccine makers for its viral-vector capabilities, Fujifilm’s CDMO arm has looked to rapidly build its US footprint to meet …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
